Caisse DE Depot ET Placement DU Quebec Boosts Position in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Caisse DE Depot ET Placement DU Quebec increased its holdings in Alnylam Pharmaceuticals by 137.2% in Q1, now owning 23,763 shares valued at approximately $6.4 million.
• Alnylam's stock price targets were raised by several analysts, with Scotiabank setting a target of $450 and HC Wainwright increasing it to $570, reflecting strong market confidence.
• Recent insider trades included significant share sales by director Dennis A. Ausiello, who sold 31,448 shares, representing a 97.18% decrease in his position.

Caisse DE Depot ET Placement DU Quebec increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 137.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,763 shares of the biopharmaceutical company's stock after buying an additional 13,745 shares during the quarter. Caisse DE Depot ET Placement DU Quebec's holdings in Alnylam Pharmaceuticals were worth $6,416,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Comerica Bank increased its stake in shares of Alnylam Pharmaceuticals by 23.3% in the first quarter. Comerica Bank now owns 17,253 shares of the biopharmaceutical company's stock valued at $4,659,000 after buying an additional 3,262 shares during the period. Jump Financial LLC increased its position in Alnylam Pharmaceuticals by 3.8% during the 1st quarter. Jump Financial LLC now owns 15,717 shares of the biopharmaceutical company's stock valued at $4,244,000 after purchasing an additional 572 shares during the period. SVB Wealth LLC acquired a new stake in Alnylam Pharmaceuticals during the 1st quarter valued at approximately $27,000. Smartleaf Asset Management LLC increased its position in Alnylam Pharmaceuticals by 19.8% during the 1st quarter. Smartleaf Asset Management LLC now owns 895 shares of the biopharmaceutical company's stock valued at $240,000 after purchasing an additional 148 shares during the period. Finally, Northwestern Mutual Wealth Management Co. increased its position in Alnylam Pharmaceuticals by 10.3% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 525 shares of the biopharmaceutical company's stock valued at $142,000 after purchasing an additional 49 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on ALNY shares. Wolfe Research raised shares of Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research report on Monday, August 4th. Chardan Capital increased their target price on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Truist Financial started coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, July 21st. They set a "buy" rating and a $385.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $570.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday. Finally, JPMorgan Chase & Co. increased their target price on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Twenty-two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $412.79.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Pushkal Garg sold 1,455 shares of the firm's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total transaction of $666,986.55. Following the completion of the sale, the executive vice president directly owned 20,221 shares of the company's stock, valued at $9,269,508.61. This trade represents a 6.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Michael W. Bonney sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $450.00, for a total value of $5,062,500.00. Following the completion of the sale, the director directly owned 16,804 shares of the company's stock, valued at approximately $7,561,800. This trade represents a 40.10% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 57,594 shares of company stock worth $25,551,456. 1.20% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Stock Up 1.0%

Shares of ALNY traded up $4.28 during trading hours on Tuesday, reaching $450.79. The stock had a trading volume of 558,191 shares, compared to its average volume of 956,196. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $469.81. The firm has a 50-day simple moving average of $377.23 and a 200 day simple moving average of $304.58. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The company has a market capitalization of $59.09 billion, a price-to-earnings ratio of -182.78 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million for the quarter, compared to analysts' expectations of $633.54 million. During the same period last year, the business earned ($0.13) EPS. Alnylam Pharmaceuticals's quarterly revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.